基本信息
文件名称:Elinzanetant-d3-NT-814-d-sub-3-sub-生命科学试剂-MCE.pdf
文件大小:473.34 KB
总页数:1 页
更新时间:2025-05-21
总字数:约3.28千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Elinzanetant-d3

Cat.No.:HY-109171S

Synonyms:NT-814-d;BAY3427080-d

33

分?式:C??H??D?F?N?O?

分?量:671.66

作?靶点:Isotope-LabeledCompounds;NeurokininReceptor

作?通路:Others;GPCR/GProtein;NeuronalSignaling

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Elinzanetant-d3(NT-814-d3)是氘代标记的Elinzanetant.Elizanetant(NT-814)是?种具有?服活性的、选择

性NK-1,3受体拮抗剂。Elizanetant能够降低雌?醇和黄体酮?平,?于?性更年期相关的?管运动症状、睡

眠障碍等研究。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubstitutiononthePharmacokineticsofPharmaceuticals.AnnPharmacother.2019;53(2):211-